Adial Pharmaceuticals, Inc. (ADIL) Earnings History
Net Loss11 years of earnings data (2015–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Adial Pharmaceuticals, Inc. (ADIL) Earnings Overview
As of June 29, 2026, Adial Pharmaceuticals, Inc. (ADIL) reported trailing twelve-month net income of -$8M, reflecting +32.8% year-over-year growth. The company earned $-5.67 per diluted share over the past four quarters.
Looking at the long-term picture, ADIL's historical earnings data spans multiple years. The company achieved its highest annual net income of -$420,200 in fiscal 2016.
Adial Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NRXP (-$25M net income, -2336.5% margin), MTNB (-$11M net income), ALKS ($153M net income, 16.4% margin), ADIL has comparable earnings metrics. Compare ADIL vs NRXP →
ADIL Earnings vs Peers
Earnings metrics vs comparable public companies
ADIL Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$8M | +39.6% | -$8M | $-11.93 | - | - |
| 2024 | -$13M | -88.5% | -$8M | $-17.75 | - | - |
| 2023 | -$7M | +45.0% | -$7M | $-136.00 | - | - |
| 2022 | -$13M | +34.5% | -$11M | $-299.50 | - | - |
| 2021 | -$19M | -78.8% | -$19M | $-653.00 | - | - |
| 2020 | -$11M | -26.4% | -$11M | $-544.75 | - | - |
| 2019 | -$9M | +26.1% | -$8M | $-545.00 | - | - |
| 2018 | -$12M | -920.8% | -$7M | $-1527.50 | - | - |
| 2017 | -$1M | -171.2% | $-995,286 | $-130.00 | - | - |
| 2016 | $-420,200 | +48.6% | $-410,807 | $-55.00 | - | - |
| 2015 | $-817,993 | - | $-819,257 | $-107.00 | - | - |
Download Data
Export ADIL earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ADIL — Frequently Asked Questions
Quick answers to the most common questions about buying ADIL stock.
What is ADIL earnings per share (EPS)?
ADIL trailing twelve-month (TTM) diluted EPS is $-5.67, reflecting +32.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is Adial Pharmaceuticals, Inc.'s net income?
Adial Pharmaceuticals, Inc. (ADIL) trailing twelve-month net income is $-8M as of 2025. Earnings grew +32.8% year-over-year.
Is ADIL profitable?
ADIL is not currently profitable on a TTM basis, reporting a net loss of $-8M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ADIL's earnings growth rate?
ADIL compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are ADIL's profit margins?
Adial Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -170.7%.
Is ADIL growing earnings?
Yes, ADIL earnings are accelerating — EPS growth of +32.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-8M. Earnings momentum is strengthening.
What was ADIL's best earnings year?
Adial Pharmaceuticals, Inc.'s highest annual net income on record is $-420200.00, achieved in fiscal year 2016. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were ADIL's earnings last quarter?
ADIL's most recent reported quarter was Q1 2026. Net income was $-2M with diluted EPS of $-1.48. For a full breakdown of all quarters, see the quarterly earnings table on this page.